COYA Quote, Financials, Valuation and Earnings

Atea Pharmaceuticals, Inc. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of --. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Atea Pharmaceuticals, Inc.'s return on equity of -36.97%.

Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 166.97%. On the other hand Atea Pharmaceuticals, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 89.27%. Given that Coya Therapeutics, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than Atea Pharmaceuticals, Inc..

Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Atea Pharmaceuticals, Inc. has a beta of 0.159, suggesting its less volatile than the S&P 500 by 84.143%.

Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atea Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Atea Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are larger than Atea Pharmaceuticals, Inc. quarterly revenues of --. Coya Therapeutics, Inc.'s net income of -$2.1M is higher than Atea Pharmaceuticals, Inc.'s net income of -$42M. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Atea Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 25.24x versus 0.84x for Atea Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of 12.65%. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Electromed, Inc.'s return on equity of 18.89%.

Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 166.97%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Coya Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than Electromed, Inc..

Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Coya Therapeutics, Inc.'s net income of -$2.1M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 25.24x versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of 31.72%. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Eli Lilly & Co.'s return on equity of 106.26%.

Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 166.97%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.59%. Given that Coya Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Coya Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Coya Therapeutics, Inc.'s net income of -$2.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 49.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 25.24x versus 15.50x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Picard Medical has a net margin of -59.36% compared to Coya Therapeutics, Inc.'s net margin of --. Coya Therapeutics, Inc.'s return on equity of -57.41% beat Picard Medical's return on equity of --.

Coya Therapeutics, Inc. has a consensus price target of $16.07, signalling upside risk potential of 166.97%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Coya Therapeutics, Inc. has higher upside potential than Picard Medical, analysts believe Coya Therapeutics, Inc. is more attractive than Picard Medical.

Coya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Coya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coya Therapeutics, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

Coya Therapeutics, Inc. quarterly revenues are $3.6M, which are larger than Picard Medical quarterly revenues of --. Coya Therapeutics, Inc.'s net income of -$2.1M is higher than Picard Medical's net income of --. Notably, Coya Therapeutics, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coya Therapeutics, Inc. is 25.24x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.